DNLI

Denali Therapeutics Inc

Feb 05 • 02:47PM ET

20.05

-1.23 -5.78 %

Healthcare • Biotechnology • USA • NASD

Today, 2:05 PMDenali Therapeutics announces new clinical data updates across its enzyme transport vehicle programs for Hunter syndrome, Sanfilippo syndrome type A, and Pompe disease at the 2026 WORLDSymposium, including long-term Phase 1/2 results supporting the tividenofusp alfa BLA under FDA Priority Review and encouraging preliminary biomarker and safety data for DNL126.

Peers: BIIB REGN ALNY UTHR IONS MRNA SRPT NBIX VRTX PTCT

| Held by: XBI IWM VTI VB VBK VXF IWN IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.91	Insider Own	10.40%	Shs Outstand	146.63M	Perf Week	-7.13%
Market Cap	3.13B	Forward P/E	-	EPS next Y	-2.81	Insider Trans	-0.36%	Shs Float	139.92M	Perf Month	16.50%
Enterprise Value	2.33B	PEG	-	EPS next Q	-0.74	Inst Own	91.96%	Short Float	10.62%	Perf Quarter	34.38%
Income	-498.74M	P/S	-	EPS this Y	-15.14%	Inst Trans	3.01%	Short Ratio	9.02	Perf Half Y	39.72%
Sales	0.00M	P/B	3.17	EPS next Y	5.13%	ROA	-39.75%	Short Interest	14.86M	Perf YTD	21.44%
Book/sh	6.32	P/C	3.69	EPS next 5Y	0.25%	ROE	-44.44%	52W High	24.34 -17.64%	Perf Year	-12.79%
Cash/sh	5.43	P/FCF	-	EPS past 3/5Y	-2.44% -4.46%	ROIC	-51.87%	52W Low	10.57 89.69%	Perf 3Y	-33.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.26% 6.49%	Perf 5Y	-70.73%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.30%	Oper. Margin	-	ATR (14)	1.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.79	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	52.69	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	9.79	EPS Q/Q	-16.35%	SMA20	1.66%	Beta	1.02	Target Price	32.86
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	8.08%	Rel Volume	0.59	Prev Close	21.28
Employees	422	LT Debt/Eq	0.04	Earnings	Nov 06 AMC	SMA200	27.03%	Avg Volume	1.65M	Price	20.05
IPO	Dec 08, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.03% -100.00%	Trades		Volume	800,325	Change	-5.78%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Buy	$25
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight	$41 → $33
Feb-11-25	Initiated	Deutsche Bank	Buy	$31
Jan-07-25	Initiated	Robert W. Baird	Outperform	$31
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy	$37
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy	$32
Nov-20-23	Resumed	JP Morgan	Overweight	$28
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$85 → $35
Sep-06-23	Initiated	B. Riley Securities	Buy	$38
Jan-30-23	Initiated	SVB Securities	Outperform	$50
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy	$38
Nov-02-22	Initiated	BofA Securities	Buy	$40
Jun-23-22	Initiated	Berenberg	Buy	$39
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform	$85

Show Previous Ratings

Today 02:00PM	Denali Therapeutics Presents Enzyme TransportVehicle Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium (GlobeNewswire) -5.78%
Feb-03-26 10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
Feb-02-26 08:00AM	Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle Programs at the 2026 WORLDSymposium (GlobeNewswire)
Jan-29-26 04:00PM	Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium (GlobeNewswire)
Jan-20-26 10:42AM	3 Biotech Stocks That Could Double In 2026 (24/7 Wall St.)
01:01PM	Loading…
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-06-26 08:00AM	Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome (GlobeNewswire) +7.43%
Dec-30-25 08:00AM	The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) (GlobeNewswire)
Dec-29-25 09:13AM	3 Biotech Stocks With Major 2026 Catalysts (Zacks)
Dec-22-25 06:11AM	Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? (Insider Monkey)
Dec-10-25 04:58PM	Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More (Motley Fool) -10.63%
12:14AM	Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-09-25 04:01PM	Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
07:00AM	Loading…
Dec-04-25 07:00AM	Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement (GlobeNewswire) +5.84%
Nov-10-25 08:19PM	H.C. Wainwright Reiterates "Buy" Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results (Insider Monkey) +12.69%
Nov-07-25 01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
Nov-06-25 04:01PM	Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
04:00PM	Denali Therapeutics Announces Board and Executive Leadership Updates (GlobeNewswire)
Oct-14-25 08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
07:53AM	AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance (BioPharma Dive)
Oct-13-25 04:01PM	Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Sep-10-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? (Zacks)
Aug-12-25 08:18AM	DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 (Zacks) -5.03%
Aug-11-25 04:01PM	Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-25 05:15AM	Clinical trial supply chains in the US navigate pharma tariffs (Clinical Trials Arena)
Aug-05-25 09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-31-25 11:58AM	Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy (Insider Monkey)
Jul-30-25 08:55AM	Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue? (Zacks)
08:15AM	Loading…
Jul-17-25 08:15AM	Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Companys Board of Directors (GlobeNewswire)
Jul-16-25 09:38AM	BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target (Insider Monkey)
Jul-08-25 09:59AM	DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review (Zacks)
Jul-07-25 08:00AM	Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) (GlobeNewswire)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-05-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? (Zacks)
May-07-25 01:10PM	Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus (Zacks)
May-06-25 04:01PM	Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome (GlobeNewswire) -12.63%
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
Apr-29-25 06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-03-25 09:32AM	DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up (Zacks) -6.91%
Apr-02-25 08:00AM	Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program (GlobeNewswire) +11.80%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 02:16PM	Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (SeekingAlpha)
08:57AM	Why You Shouldn't Bet Against Denali (DNLI) Stock (Zacks)
Mar-04-25 08:00AM	Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer (TipRanks)
Mar-03-25 12:49PM	Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos Investments in 2025? (Insider Monkey) -8.21%
Feb-27-25 04:01PM	Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) -10.97%
Feb-06-25 11:42AM	Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa (GlobeNewswire)
Jan-30-25 08:00AM	Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium (GlobeNewswire)
Jan-17-25 11:18AM	Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-13-25 08:00AM	Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire)
Jan-08-25 08:00AM	Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) (GlobeNewswire)
07:25AM	Denali Therapeutics price target lowered to $32 from $35 at BTIG (TipRanks)
Jan-07-25 04:33PM	These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com) +6.86%
04:08PM	Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment (Investor's Business Daily)
02:16PM	These Stocks Are Moving the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com)
12:48PM	Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected (Benzinga)
10:13AM	Denali Therapeutics Phase II/III trial of ALS therapy fails to meet primary endpoint (Clinical Trials Arena)
10:13AM	Denali Therapeutics ALS therapy fails to meet primary endpoint in Phase II/III trial (Clinical Trials Arena)
09:33AM	Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. (Investor's Business Daily)
04:41AM	ALS drugs from Denali, Calico come up short, marking setback for Healey trial (BioPharma Dive)
Jan-06-25 04:30PM	Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire) -6.77%
Jan-03-25 01:08PM	Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic (Benzinga)
Dec-17-24 06:25AM	Denali Therapeutics upgraded to Buy from Hold at Stifel (TipRanks)
Dec-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? (Zacks) +6.73%
Dec-05-24 08:00AM	Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease (GlobeNewswire)
Nov-06-24 04:01PM	Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.87%
Oct-29-24 10:01AM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-13-24 04:56PM	Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Sep-16-24 11:22AM	Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? (Zacks)
Sep-04-24 08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 08:00AM	Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Aug-19-24 10:13AM	Genetic testing in Parkinsons disease patients: a standard of care imperative? (Medical Device Network)
Aug-14-24 02:00PM	Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration (GlobeNewswire)
Aug-06-24 09:55AM	Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade (Zacks)
Aug-01-24 06:45AM	Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-23-24 06:13AM	Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? (Zacks)
Jul-16-24 03:19PM	Denali Therapeutics Stock Gets Technical Rating Upgrade (Investor's Business Daily)
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-28-24 08:37AM	Denali (DNLI) Outperforms Industry in 3 Months: Here's Why (Zacks)
Jun-24-24 09:07AM	Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last? (Zacks)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
Jun-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report? (Zacks)
Jun-04-24 01:17PM	Denali's (DNLI) Candidate Selected for FDA's START Pilot Program (Zacks)
Jun-03-24 08:00AM	Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies (GlobeNewswire) +9.81%
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-08-24 11:17AM	Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating (MT Newswires) +12.17%
09:16AM	Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating (MT Newswires)
08:20AM	Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus (Zacks)
May-07-24 10:56PM	DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:56PM	Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts (GuruFocus.com)
04:01PM	Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-01-24 08:00AM	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire)
Apr-09-24 08:46AM	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick (Zacks)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 11:30AM	Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? (Zacks)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Feb-28-24 08:08AM	Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) -13.45%

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CAROLE HO	Former Affiliate	Feb 04 '26	Proposed Sale	21.18	150,000	3,176,970		Feb 04 04:16 PM
CAROLE HO	Former Affiliate	Feb 03 '26	Proposed Sale	22.16	150,000	3,324,060		Feb 03 04:47 PM
Watts Ryan J.	President and CEO	Jan 06 '26	Sale	16.50	35,198	580,767	296,833	Jan 08 04:20 PM
Schuth Alexander O.	COFO and Secretary	Jan 06 '26	Sale	16.50	17,218	284,097	282,828	Jan 08 04:19 PM
Ho Carole	Consultant	Jan 06 '26	Proposed Sale	16.50	17,218	284,097		Jan 06 08:28 PM
Schuth Alexander O.	Officer	Jan 06 '26	Proposed Sale	16.50	17,218	284,097		Jan 06 08:25 PM
Watts Ryan J.	Director	Jan 06 '26	Proposed Sale	16.50	35,198	580,767		Jan 06 08:24 PM
CAROLE HO	Officer	Dec 04 '25	Proposed Sale	19.00	1,882	35,758		Dec 04 04:41 PM
Schuth Alexander O.	COFO and Secretary	Aug 12 '25	Sale	13.58	2,937	39,884	242,346	Aug 14 08:33 PM
Ho Carole	Chief Medical Officer	Aug 12 '25	Sale	13.58	2,937	39,884	217,391	Aug 14 08:33 PM
Ho Carole	Chief Medical Officer	Aug 13 '25	Sale	14.64	806	11,800	216,585	Aug 14 08:33 PM
CAROLE HO	Officer	Aug 13 '25	Proposed Sale	13.22	806	10,655		Aug 13 04:45 PM
Schuth Alexander O.	Officer	Aug 12 '25	Proposed Sale	13.58	2,937	39,876		Aug 12 08:46 PM
Ho Carole	Officer	Aug 12 '25	Proposed Sale	13.58	2,937	39,876		Aug 12 08:44 PM
Ho Carole	Chief Medical Officer	Aug 05 '25	Option Exercise	0.68	44,655	30,365	220,328	Aug 07 05:34 PM
Watts Ryan J.	President and CEO	Jul 09 '25	Option Exercise	1.05	495,282	520,792	748,353	Jul 11 05:13 PM
Watts Ryan J.	President and CEO	Jul 09 '25	Sale	15.00	495,282	7,429,230	253,071	Jul 11 05:13 PM
Watts Ryan J.	Officer	Jul 09 '25	Proposed Sale	14.33	495,282	7,097,391		Jul 09 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DNLI

Denali Therapeutics Inc

Upgrade your FINVIZ experience